本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
HONG KONG, Oct. 25, 2024 /PRNewswire/ -- Prudential Hong Kong Limited ("Prudential") is proud to be the first insurer in Hong Kong to launch MedScreen+, an innovative digital underwriting tool developed in collaboration with Reinsurance Group of America, Incorporated ("RGA"), a leading global life and health reinsurer. The launch of MedScreen+ exemplifies Prudential's commitment to leverage technology and innovation in our distribution channels to provide our customers with superior underwriting. By leveraging optical character recognition ("OCR") and AI technology, coupled with RGA's proprietary digital underwriting engine, MedScreen+ can assess medical reports in less than half the time needed when using traditional methods, providing a fast, simple, and transparent underwriting process for underwriters, while supporting our financial consultants in providing instant and indicative underwriting results to customers at the application stage for a better, more seamless onboarding journey. MedScreen+ is capable of processing over 160 lab tests, including blood tests, ultrasounds, urine tests, ECG, CXR, CT chest and other tests, to assess a variety of routine health check-ups and medical requirements and provide indicative underwriting outcomes, making the underwriting process more efficient and consistent. By automatically processing results from check-up findings, underwriters are able to focus on more complex assessment and synthesising information, rather than sifting through pages of medical test results. Candy Au Yeung, Chief Customer Operations and Health Officer at Prudential Hong Kong Limited, said: "We recognise the importance of providing swift protection for our customers. In response to this critical need, we introduced this innovative solution to streamline our underwriting process, in partnership of RGA. This initiative underscores our commitment to being a forward-thinking, customer-centric company, dedicated to delivering efficient solutions that meet the evolving needs of our customers." Carmony Wong, Senior Vice President, Southeast Asia Markets & Chief Executive Officer, Hong Kong at Reinsurance Group of America, Incorporated, said: "I am thrilled to announce our partnership with Prudential to launch MedScreen+, an innovative first-in-market solution that empowers insurance companies to enhance their underwriting journey. This collaboration underscores our shared commitment to customer excellence and our dedication to digitally enabling the customer experience. Together, we are paving the way for a more efficient insurance landscape in Hong Kong that is oriented around customer needs." About Prudential Hong Kong LimitedPrudential has been serving the people of Hong Kong since 1964. Through Prudential Hong Kong Limited and Prudential General Insurance Hong Kong Limited, we provide a range of financial planning services and products including individual life insurance, investment-linked insurance, retirement solutions, health and medical protection, general insurance, and employee benefits to protect over 1.3 million customers in Hong Kong. In 2023, Prudential established its Macau branch to offer health insurance and financial solutions for the Macau community, completing its footprint in the Greater Bay Area. Please visit www.prudential.com.hk for more information.
HONG KONG and SHANGHAI, Oct. 21, 2024 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An", or the "Group", HKEX: 2318 / 82318; SSE: 601318) today announced its results for the nine months ended September 30, 2024. In the first nine months of 2024, China's economy remained generally stable as it pursued high-quality development amidst short-term challenges including economic restructuring, lackluster growth momentum, and increasing external uncertainties. Ping An achieved steady growth with strong resilience in overall business performance by adhering to its core financial businesses, strengthening its "integrated finance + health and senior care" strategy under a customer-centric approach, and delivering "worry-free, time-saving, and money-saving" service experience. The Group delivered a 15.9% annualized operating return on equity (ROE), with operating profit and net profit attributable to shareholders of the parent company rising 5.5% and 36.1% year on year to RMB113,818 million and RMB119,182 million respectively in the first nine months of 2024. Revenue increased 8.7% year on year to RMB861,817 million*. Three core businesses, namely life and health insurance (Life & Health), property and casualty insurance (Ping An P&C), and banking, maintained positive growth and delivered RMB119,651 million in operating profit attributable to shareholders of the parent company, up 5.7% year on year. Life & Health achieved high-quality development and new business value (NBV) amounted to RMB35,160 million in the first nine months of 2024, up 34.1% year on year. Customers entitled to health and senior care services contributed over 69.6% of Ping An Life's NBV in the first nine months of 2024. Deepened "4 channels + 3 products" strategy; Life & Health NBV surged 34.1% year on year Life & Health improved operational quality and efficiency, leading to significant result in high-quality development. Ping An Life continued to enhance its channels and improve business quality under the "4 channels + 3 products" strategy in the first nine months of 2024. By upgrading "insurance + service" solutions, the company continuously strengthened its presence in health and senior care sectors. Life & Health NBV grew 34.1% year on year to RMB35,160 million in the first nine months of 2024. NBV margin based on annualized new premium (ANP) rose by 5.7 pps year on year to 31.0%. Ping An Life enhanced its channel capabilities under the value orientation of high-quality development. The company continued to deepen the transformation and build multichannel professional sales capabilities, significantly improving the development quality. Agent channel NBV grew 31.6% year on year in the first nine months of 2024. Ping An Life also effectively improved agent productivity, boosting NBV per agent by 54.7% year on year. The company focused on recruiting high-quality new agents through high-quality existing ones. The number of individual life insurance sales agents was about 362,000 as of September 30, 2024. The proportion of "Talent +" agents increased by 4 pps year on year in new recruits. In respect of cooperation with banks, Ping An Life increased NBV of the bancassurance channel by 68.5% year on year by enhancing outlet operations. The company continuously developed the community finance channel. The 13-month persistency ratio of orphan polices within this channel improved by 6.6 pps year on year in the first nine months of 2024, with NBV up by over 300% year on year. Innovative channels including bancassurance and community finance accounted for 18.8% of Ping An Life's NBV in the first nine months of 2024, up by 2.4 pps year on year. Ping An Life diversified and upgraded its product portfolio under a customer-centric philosophy. Playing a role of a shock absorber and stabilizer in the insurance sector, the company focused on core customer demands for health protection, pension reserves, and wealth management. It consistently diversified and upgraded its insurance product portfolio under a customer-centric approach. By leveraging the Group's health and senior care ecosystem, Ping An Life continuously improved "insurance + service" products. In respect of health care, Ping An Life provided health management services to over 19.50 million customers in the first nine months of 2024. In respect of home-based senior care, Ping An innovated its "medical, nursing, housing and entertainment" alliances, continuously working with its partners to establish service standards and ecosystems. Ping An's home-based senior care services covered 75 cities across China as of September 30, 2024 with over 150,000 customers eligible for such services, who gave positive general feedback. Ping An unveiled premium senior care communities in five cities as of September 30, 2024, which are currently under construction and will be open for business from 2025 onward. Ping An P&C and banking businesses maintained stable growth; technology enabled financial businesses to boost quality and efficiency Ping An P&C maintained stable revenue growth and good business quality. In the first nine months of 2024, the company's insurance revenue and operating profit increased 4.5% and 39.7% year on year to RMB246,022 million and RMB13,987 million respectively. Ping An P&C improved its overall combined ratio (COR) by 1.5 pps year on year to 97.8% through enhanced business management and risk screening, leading the market. Ping An Bank maintained resilient business performance as well as adequate capital and risk provisions. The bank's net profit grew 0.2% year on year to RMB39,729 million in the first nine months of 2024. Retail assets under management (AUM) rose by 2.9% from the beginning of the year to RMB4,148,566 million as of September 30, 2024. Corporate loan balance grew 11.6% from the beginning of the year to RMB1,595,924 million as of September 30, 2024. Core tier 1 capital adequacy ratio rose to 9.33% and the provision coverage ratio stood at 251.19%; non-performing loan ratio remained flat from the beginning of the year at 1.06% as of September 30, 2024. Ping An delivered excellent results in insurance funds investment. The Group's insurance funds investment portfolio grew 12.7% from the beginning of the year to over RMB5.32 trillion as of September 30, 2024. Under a philosophy of value investing through cycles, the insurance funds investment portfolio achieved an annualized comprehensive investment yield of 5.0%, up by 1.3 pps year on year. From the perspective of transforming and upgrading Ping An's core financial businesses, technology benefits are reflected in higher sales, better business efficiency, and stronger risk management. The volume of services provided by Ping An's artificial intelligence (AI) service representatives reached about 1.34 billion times, accounting for 80% of total customer service volume in the first nine months of 2024. The AI service representatives responded to and handled customer inquiries and complaints swiftly. Via smart underwriting and smart claim settlement, 93% of Ping An Life's policies were underwritten within seconds, and it took an average of 7.4 minutes to close a claim with Smart Quick Claim. Moreover, claims savings via smart fraud risk identification amounted to RMB9.1 billion in the first nine months of 2024 as Ping An continuously strengthened risk management. The Group's patent applications led most international financial institutions, totaling 53,521 and including generative AI patent filings in terms of which Ping An ranked second in the world. Enhancing the "integrated finance + health and senior care" strategy to provide "worry-free, time-saving, and money-saving" customer service experience Ping An further advanced integrated finance business and upgraded it from cross-selling to comprehensive customer-centric operation. Ping An built a needs-oriented, customer-centric operation system characterized by digital operations. On the basis of data mining, Ping An leveraged customer insights, product benefits and a smart marketing service platform to improve customer acquisition, activation, migration and retention, providing "worry-free, time-saving, and money-saving" one-stop integrated finance solutions. The Group's retail customers increased 3.8% from the beginning of the year to 240 million as of September 30, 2024. The customer retention increased, with 25.1% of customers holding four or more contracts within the Group, resulting in a retention rate of 98.0%. Retail cross-selling continued to deepen as approximately 16.88 million times of cross-selling occurred within the Group in the first nine months of 2024. As of September 30, 2024, over 88.26 million retail customers held multiple contracts with different subsidiaries of the Group. Contracts per retail customer reached 2.92. Retail customers and contracts per retail customer have increased 21.3% and 9.4% respectively since December 31, 2019 to September 30, 2024. Ping An continuously implemented its health and senior care strategy to build significant differential advantages. Nearly 63% of Ping An's 240 million retail customers used services from the health and senior care ecosystem as of September 30, 2024. They held approximately 3.35 contracts and RMB57,800 in AUM per capita, 1.6 times and 3.9 times those held by non-users of these services respectively. The health and senior care ecosystem is becoming an increasingly important enabler to Ping An Life's core businesses. Over 19.50 million customers of Ping An Life used services from the health and senior care ecosystem in the first nine months of 2024. Approximately 76% of Ping An Life's newly enrolled customers used health management services in the first nine months of 2024. Customers entitled to health and senior care services contributed over 69.6% of Ping An Life's NBV, including approximately 39.0% from those entitled to senior care services and approximately 30.6% from those entitled to health care services. Ping An made significant progress in developing health management and medical service networks. The Group maintained exclusive health records for customers, and provided membership-based health and senior care services via family doctors and senior care concierges. Ping An guided members through an end-to-end "online, in-store, and in-home" service network covering consultation, diagnosis, treatment and services under AI-enabled 24/7 seconds-level management. Its health and senior care ecosystem had nearly 64,000 paying corporate customers, serving their over 26 million employees as of September 30, 2024. PKU Healthcare Group's revenue continued to grow and reached approximately RMB3.93billion in the first nine months of 2024. Meanwhile, Ping An integrated domestic and overseas premium resources including medical services, health services, commodities and medicines to build extensive partner networks in China and abroad. Ping An had about 50,000 in-house doctors and contracted external doctors in China as of September 30, 2024. Ping An has partnered with over 36,000 hospitals (including all top 100 hospitals and 3A hospitals), over 104,000 health care management institutions and over 233,000 pharmacies in China. Overseas, Ping An has partnered with over 1,300 health care institutions in 35 countries. Ping An actively fulfilled its social responsibilities and served green development and rural vitalization. Ping An's green insurance premium income amounted to RMB37,341 million and funds provided for rural industrial vitalization via "Ping An Rural Communities Support" totaled RMB31,406 million in the first nine months of 2024. The Group remained No.1 in the financial industry on China Central Television (CCTV)'s "China's Top 100 Listed Companies by ESG" list in 2024. Looking ahead, the fundamentals of China's economic development remain unchanged, with great market potential and strong economic resilience continuing to provide favorable conditions. As the state effectively implements various decisions and a series of incremental policies, China's growth momentum will gradually strengthen. The economic trend of continued stability with steady progress will be further bolstered. The health care, senior care and financial markets are poised to embrace new growth opportunities. To achieve high-quality business development, Ping An will uphold a people-centric philosophy, maintain its strategic focus on core financial businesses, advance its technology-driven "integrated finance + health and senior care" strategy, improve operations and management to drive business recovery and growth, and continually enhance the quality and effectiveness of financial services for the real economy. Ping An is committed to creating long-term, stable and sustainable value for customers, employees, shareholders and society, as well as contributing to China's development into a financial powerhouse. * Based on the International Financial Reporting Standards issued by the International Accounting Standards Board
KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 21 October 2024 – Chubb today announced the appointment of Jon Longmore as Country President of Malaysia, effective early November and subject to regulatory and other approvals. Currently Country President of PT Chubb General Insurance Indonesia, Longmore succeeds Stephen Crouch, who has been appointed Head of Government Affairs, Asia Pacific. In his new role, Longmore will have responsibility for the overall performance of Chubb in Malaysia. He will be based in Kuala Lumpur and continue reporting to Marcos Gunn, Regional President, Asia Pacific. Longmore began his 13-year career with Chubb in a series of underwriting, distribution and partnership roles while based in Australia. He was appointed Head of Digital for Asia Pacific in 2018 before assuming his latest role as Country President of PT Chubb General Insurance in 2020. On announcing Longmore's appointment, Gunn said, "Jon is an experienced international insurance professional with a track record of driving sustainable business growth. His keen focus on innovation and passion for building teams position him well to further grow our business in Malaysia." Longmore holds a Bachelor of Arts in International Relations from the University of Queensland. Adrianto Gunawan, Chief Financial Officer for Indonesia, will take on the additional role of interim Country President while the appointment of a permanent successor is underway. Hashtag: #ChubbThe issuer is solely responsible for the content of this announcement.About ChubbChubb is a world leader in insurance. With operations in 54 countries and territories, Chubb provides commercial and personal property and casualty insurance, personal accident and supplemental health insurance, reinsurance and life insurance to a diverse group of clients. As an underwriting company, we assess, assume and manage risk with insight and discipline. We service and pay our claims fairly and promptly. The company is also defined by its extensive product and service offerings, broad distribution capabilities, exceptional financial strength and local operations globally. Parent company Chubb Limited is listed on the New York Stock Exchange (NYSE: CB) and is a component of the S&P 500 index. Chubb maintains executive offices in Zurich, New York, London, Paris and other locations, and employs more than 40,000 people worldwide. Additional information can be found at: www.chubb.com.
HONG KONG, Oct. 18, 2024 /PRNewswire/ -- China Ping An Insurance Overseas (Holdings) Limited, the main offshore investment and asset management platform of Ping An Insurance (Group) Company of China, Ltd. (2318.HK, 601318.SH), together with its subsidiaries ("PAOH" or "Ping An"), announces the successful closing of its third vintage of private equity fund program (the "Fund"). The Fund is a continuation of PAOH's dedicated investment program focusing on the overseas private equity market. It comprises a well-diversified portfolio of top-tier buyout and growth managers in North America and Europe which was invested by Ping An and was transferred to the Fund as a secondary transaction. The Fund also includes a mandate that will invest in co-investment opportunities sourced from Ping An's extensive network of global GP relationships. The Fund received a total capital commitment of USD 850 million from a group of global investors, led by AlpInvest Partners ("AlpInvest") and Montana Capital Partners ("mcp"). GIC, which previously anchored a predecessor private equity fund managed by PAOH with mcp, has participated in the Fund as well. PAOH and other investors are also limited partners in the Fund. Hoi Tung, Chairman and CEO of PAOH, commented: "We are delighted to see the successful closing of our third fund vintage. We are particularly grateful for the support of our existing investors, GIC and mcp, as well as the trust of AlpInvest and other limited partners. This is a great vote of confidence and recognition in our investment capability, track record and operational governance. We look forward to capturing more compelling investment opportunities in the global market for our prestigious partners." Dr. Christoph Jäckel, Managing Partner of mcp, said: "We are honored to deepen our long-standing relationship with Ping An by structuring another customized and complex carve-out transaction. This secondary investment opportunity is a great showcase for mcp's ability to add value for our investors by providing exposure to high-quality private equity assets in unique ways through direct negotiations." Choo Yong Cheen, Chief Investment Officer of Private Equity at GIC, noted: "GIC is pleased to extend our relationship with Ping An, along with AlpInvest and Montana Capital, through another secondary transaction following the success of our prior commitment. Ping An has continued to invest with well-regarded managers, creating another compelling opportunity for GIC." Wendy Zhu, Managing Director at AlpInvest Partners said, "We are excited to partner with PAOH in identifying and building out a high quality global private equity portfolio managed by our selected global private equity managers. We look forward to the collaboration between our firms and to support PAOH in building an industry-leading asset management franchise."
HONG KONG and SHANGHAI, Oct. 18, 2024 /PRNewswire/ -- The Weight Management and Public Health Action Conference, hosted by the National Center for Chronic and Noncommunicable Disease Control and Prevention ("NCNCD") and its affiliated institution, the Binhai Institute for Chronic Disease Control and Prevention and Health Innovation, and co-organized by Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK), recently concluded successfully. At the conference, Ping An Health announced a comprehensive upgrade to its chronic disease management services, expanding from "Three Controls and One Reduction" (blood sugar control, blood pressure control, and weight management) to "Five Controls and One Reduction." The upgraded program incorporates prevention and management solutions for fatty liver disease, hyperuricemia, and hyperlipidemia. It also includes comprehensive plans for integrating and connecting intelligent wearable devices and offline medical services. This upgrade significantly expands the scope of chronic disease control and prevention, providing customers with more comprehensive health management services. Additionally, Ping An Health has signed agreements with major tertiary hospitals, including Guangdong Second Provincial General Hospital, to jointly promote online and offline collaborative projects for chronic disease reversal, such as the reversal of diabetes and obesity. These initiatives create new avenues for customers to achieve worry-free, time-saving, and money-saving healthcare. Furthermore, NCNCD released the Digital Weight Management Research Report based on Ping An Health's chronic disease management program. The report highlights Ping An Health's digital weight management program, leveraging Ping An Jin Guan Jia and enterprise WeChat groups as primary management tools, effectively implemented a short-term, intensive training camp model for online adult weight management. Participants in the training camp achieved an average weight reduction of 1.5kg and a decrease in body mass index (BMI) of 0.6kg/m2, demonstrating a positive impact on improving their physical fitness. The program effectively reduced the proportion of overweight and obese individuals among participants within a specific timeframe, signifying its positive public health implications. NCNCD also joined forces with Ping An Health to launch the Intelligent Health Management Public Welfare Project for Professionals. This initiative aims to leverage Ping An Health's digital technology and intelligent tools to provide comprehensive health management services for employees across various enterprises nationwide, assisting them in effectively managing their weight and preventing chronic diseases. – End – About Ping An Healthcare And Technology Company Limited Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company"; Stock Code: 1833.HK), established in 2014, is the flagship of Ping An's healthcare and elderly care ecosystem. The Company was listed on the Main Board of HKEX on 4 May 2018. Ping An Health has leveraged its core competencies to enhance its managed care strategy. These competencies include rich payer resources for healthcare services such as insurance and financial clients, as well as corporate clients. Ping An Health is also empowered by its extensive supplier network, comprehensive service standard system, and strong Ping An ecosystem. Moreover, the Company is committed to building two main strategic pillars: "family doctor" and "senior care concierges". They focus on professional, comprehensive, high-quality, one-stop healthcare and senior care management services. Going forward, Ping An Health will adhere to the value proposition of "worry-free, time-saving and money-saving", with the vision "to provide every enterprise with a harmonious workplace, every family with a dedicated doctor, and every user with a safe and healthcare life". The Company will improve products with "ingenuity" and establish reputation with quality. Ping An Health will provide sustainable long-term value to users, shareholders and society through bridging doctors and patients with professionalism and safeguard everyone's health.
This approval for XPOVIO® for the treatment of patients with multiple myeloma (MM) marks the third approved indication of the drug in South Korea. To date, XPOVIO® has already been included in national health insurance or reimbursement schemes in South Korea, the mainland of China, Australia and Singapore, and is expected to achieve national reimbursement coverage in more APAC markets. XPOVIO® has been approved for multiple indications in nine markets across the APAC region. Antengene has submitted a new drug application (NDA) for XPOVIO® in Indonesia with approval expected in the second half of 2024. SHANGHAI and HONG KONG, Oct. 18, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that the South Korean Ministry of Food and Drug Safety (MFDS) has approved a supplemental New Drug Application (sNDA) for XPOVIO® (selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy. Prior to the recent approval, XPOVIO® has been approved for two indications in South Korea that are: in combination with dexamethasone for the treatment of adult patients with relapsed or refractory MM (R/R MM); and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). In July 2024, XPOVIO® was included into the reimbursement drug list in South Korea, thus became the first XPO1 inhibitor approved for public insurance coverage in the country. With a novel mechanism of action, XPOVIO® is the world's first approved orally-available, selective XPO1 inhibitor, which has already been approved in nine countries and regions in APAC and included in the national insurance schemes in South Korea, the mainland of China, Australia, and Singapore. This recent approval for XPOVIO® in South Korea will bring another innovative therapy to the clinical management of MM patients in South Korea, benefiting countless patients and families. While bringing XPOVIO® to more APAC markets, Antengene is also striving to expand the indications of XPOVIO®. Leveraging the drug's novel mechanism of action, Antengene is currently developing multiple combination regimens of XPOVIO® for the treatment of various indications including myelofibrosis (MF), and endometrial cancer. About XPOVIO® (selinexor) XPOVIO® is the world's first approved orally-available, selective inhibitor of the nuclear export protein XPO1. It offers a novel mechanism of action, synergistic effects in combination regimens, fast onset of action, and durable responses. By blocking the nuclear export protein XPO1, XPOVIO® can promote the intranuclear accumulation and activation of tumor suppressor proteins and growth regulating proteins, and down-regulate the levels of multiple oncogenic proteins. XPOVIO® delivers its antitumor effects through three mechanistic pathways: 1) exerting antitumor effects by inducing the intranuclear accumulation of tumor suppressor proteins; 2) reducing the level of oncogenic proteins in the cytoplasm by inducing the intranuclear accumulation of oncogenic mRNAs; 3) restoring hormone sensitivity by activating the glucocorticoid receptors (GR) pathway. To utilize its unique mechanism of actions, XPOVIO® is being evaluated for use in multiple combination regimens in a range of indications. At present, Antengene is conducting multiple clinical studies of XPOVIO® in the mainland of China for the treatment of relapsed/refractory hematologic malignancies and solid tumors (3 of these studies are being jointly conducted by Antengene and Karyopharm Therapeutics Inc. [Nasdaq:KPTI]). About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 29 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2023, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact: Investor Contacts: Donald LungE-mail: Donald.Lung@antengene.com Mobile: +86 18420672158 PR Contacts:Peter QianE-mail: Peter.Qian@antengene.com Mobile: +86 13062747000
A12 藝術空間
Health Insurance
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
